OneSource Specialty Pharma Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 6 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹17.8K Cr
Significant revenue growth expected driven by multiple MSA executions and capacity expansions (Page 8). Q2 FY26 showed strong revenue growth and a 37% rise in EBITDA with a 500+ bps margin expansion.
From OneSource Specialty Pharma Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,535
Market Cap
₹17.8K Cr
How does OneSource Specialty Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare OneSource Specialty Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
OneSource Specialty Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹428 Cr, net profit ₹5 Cr.
Full financials →📊 Revenue & Sales Performance
- →Significant revenue growth expected driven by multiple MSA executions and capacity expansions (Page 8).
- →Accelerated capacity expansion to 220 million units by end of CY 2026 to support anticipated demand (Pages 9, 16).
- →Expectation of eight to ten customers launching products globally in FY 2027 boosting commercial supply (Page 6).
- →Current capacity utilization is uncertain but expected to increase in phases through 2026 (Page 18).
- →Customers involved in capacity capex and reservation fees indicating strong demand and long-term partnerships (Pages 10, 16).
- →Confidence in capturing customer demand as capacity added progressively in phases through calendar year 2026 (Page 18).
- →Revenue recognition depends on regulatory approvals by customers; thus, some timing ambiguity in near term (Pages 16, 18).
- →Medium-term outlook supported by current capacity plans; future expansions anticipated outside India as needed (Page 9).
📈 Profitability & Margins
- →Q2 FY26 showed strong revenue growth and a 37% rise in EBITDA with a 500+ bps margin expansion.
- →Full capacity is sold out, with an accelerated capex program to support FY27 commercialization and medium-term growth.
- →Mid-term outlook targets significant revenue growth, aiming for $500 million by FY28, including contributions from acquisitions.
- →Capacity expansions in biologics and drug-device combinations support expected demand surge.
- →Revenue recognition currently uncertain due to contract terms and regulatory approvals but expected to improve from FY27 onwards.
- →Adjusted EPS for Q2 FY26 was INR 3.9 per share on a fully diluted basis.
- →Positive PAT reported in Q2, improving from negative in prior year.
- →Long-term growth driven by capacity expansion, customer base diversification, and regulatory approvals across markets.
🏗️ Capital Expenditure Plans
- →OneSource Specialty Pharma is actively accelerating its Phase 2 capacity expansion to support FY ’27 commercialization plans for the DDC (drug-device combination) business.
- →The company is investing significantly in capital expansion, evidenced by increased net debt and prepaid high-cost debt to maintain financial discipline.
- →Capacity additions are planned in phases through calendar year 2026, including expansions by May/June, September/October, and end of year.
- →There is also an intention to expand biologics capacity beyond the current 4 kL installed, with plans to almost double it to 8 kL through limited capex.
- →Future capacity expansions outside India are being considered, with Warsaw operations cited as a potential site for next expansion.
- →Customers are contributing to capex programs or reservation fees to secure capacity in advance.
- →Overall, capex is focused on enabling medium-term growth and meeting increased customer demand, especially for complex products like GLP-1 injectables and biologics.
💰 Fundraising & Capital Structure
- →The company is currently focused on capital expansion and has accelerated its Phase 2 capacity expansion plans for FY '27 commercialization.
- →Since listing in January 2025, OneSource Specialty Pharma Limited has had multiple credit rating upgrades, now in the A family, enabling financing on better terms.
- →The effective interest rate has improved, down 140 basis points versus prior year, now in single digits.
- →They have prepaid a significant amount of high-cost debt and are taking a balanced funding approach.
- →No explicit mention of immediate plans for new fundraising through debt or equity on page 19 or surrounding pages.
- →Future expansions outside India will be considered as needed, implying potential future capital needs, but no direct current fundraising announced.
📋 Order Book & Pipeline
- →The order book for OneSource Specialty Pharma Limited's drug-device combination segment remains solid.
- →Nearly 8 to 10 customers are expected to launch products across multiple global markets in the next year, driving growth.
- →The company has 50+ active RFPs (Request for Proposals) across various modalities, including soft gelatin, injectables, and biologics, indicating a healthy pipeline.
- →The company continues to receive new customer engagements, including licensing agreements and MSAs.
- →Customers are actively participating in capital expenditure plans to secure capacity, reflecting committed demand.
- →Working capital is elevated due to planned inventory buildup for future DDC launches, backed by customer advances and purchase orders.
- →The business has noted significant BD activity and outreach in biologics with traction on new programs.
- →Management cautions about near-term ambiguity due to regulatory and court-related uncertainties affecting revenue recognition, despite being fully sold out on current capacity.
Key Metrics
Frequently Asked Questions
What were OneSource Specialty Pharma Ltd Q2 FY26 results?
Significant revenue growth expected driven by multiple MSA executions and capacity expansions (Page 8). Q2 FY26 showed strong revenue growth and a 37% rise in EBITDA with a 500+ bps margin expansion.
What is OneSource Specialty Pharma Ltd share price analysis?
OneSource Specialty Pharma Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹17,817 Cr. Investors should review the full earnings analysis for detailed insights.
Is OneSource Specialty Pharma Ltd planning capital expenditure?
OneSource Specialty Pharma is actively accelerating its Phase 2 capacity expansion to support FY ’27 commercialization plans for the DDC (drug-device combination) business.
Keep OneSource Specialty Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.